» Articles » PMID: 20214740

Delta-like 1 Contributes to Cell Growth by Increasing the Interferon-inducible Protein 16 Expression in Hepatocellular Carcinoma

Overview
Journal Liver Int
Specialty Gastroenterology
Date 2010 Mar 11
PMID 20214740
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Delta-like 1 (DLK1), a fetal liver stem cell marker, is strongly expressed in human and rodent fetal liver, but not in adult liver. Notably, dysregulation of DLK1 was found in some human hepatocellular carcinomas (HCC). However, the effect of DLK1 on HCC cell growth and its underlying mechanism are still largely unknown.

Aims: To (i) assess the expression of DLK1 in human HCC and adjacent liver tissues and human HCC cell lines; (ii) evaluate the effect of DLK1 on SMMC-7721, Huh7 HCC cell growth in vitro and in vivo; and (iii) explore the potential mechanism of DLK1 that regulates HCC cell growth.

Methods: The expression of DLK1 mRNA and protein were detected using reverse transcriptase-polymerase chain reaction and immunohistochemistry respectively. The effect of DLK1 on the proliferation of SMMC-7721 and Huh7 cells was evaluated by colony formation and tumour xenograft assay. The differential expression profiles of DLK1-overexpressing SMMC-7721 cells and control cells were compared using HG-U133 Plus 2 Genechip. The cell cycle distribution of DLK1 forced expressing cells was comparatively analysed.

Results: Upregulation of DLK1 was observed in 41 of 57 (71.9%) human HCC samples. Ectopic expression of DLK1 promoted cell proliferation, colony formation and tumorigenicity in SMMC-7721 and Huh7 cells. DLK1 upregulated the expression of interferon-inducible protein 16 (IFI16) and its promoter transcriptional activity, decreased p21waf1/cip1 and induced cell cycle acceleration. However, silencing of IFI16 using small interfering RNA abrogated DLK1-induced proliferation in these cells.

Conclusions: IFI16 may be an essential downstream target of DLK1 in HCC cells and required for DLK1-induced cell proliferation.

Citing Articles

miR-130b suppresses the invasion and migration of prostate cancer via inhibiting DLL1 and regulating the PI3K/Akt pathways.

Jia L, Lei B, Gao H, Jia L, Luo D, Han J Exp Ther Med. 2022; 23(1):98.

PMID: 34976140 PMC: 8674980. DOI: 10.3892/etm.2021.11021.


Interferon-induced protein 16 expression in colorectal cancer and its correlation with proliferation and immune signature markers.

Zou Y, Zhang J, Zhang L, Yan X Oncol Lett. 2021; 22(3):687.

PMID: 34434286 PMC: 8335744. DOI: 10.3892/ol.2021.12948.


Adenomatous polyposis coli-binding protein end-binding 1 promotes hepatocellular carcinoma growth and metastasis.

Aiyama T, Orimo T, Yokoo H, Ohata T, Hatanaka K, Hatanaka Y PLoS One. 2020; 15(9):e0239462.

PMID: 32956413 PMC: 7505586. DOI: 10.1371/journal.pone.0239462.


Notch ligand Delta-like 1 as a novel molecular target in childhood neuroblastoma.

Bettinsoli P, Ferrari-Toninelli G, Bonini S, Prandelli C, Memo M BMC Cancer. 2017; 17(1):352.

PMID: 28525978 PMC: 5438559. DOI: 10.1186/s12885-017-3340-3.


Serum DLK1 is a potential prognostic biomarker in patients with hepatocellular carcinoma.

Li H, Cui M, Chen T, Xie H, Cui Y, Tu H Tumour Biol. 2015; 36(11):8399-404.

PMID: 26018510 DOI: 10.1007/s13277-015-3607-8.